Download presentation
Presentation is loading. Please wait.
Published byAusten Harris Modified over 6 years ago
1
How Can we Improve Outcomes for the Elderly Patient with AML?
3
The Challenge of Managing Older Patients With AML: EUROCARE-5 (2000-2007)
4
Front-Line Treatment Outcomes in Older Patients With AML
5
Poorer Outcomes With Undertreatment of Older Patients
6
Clinical and Biological Factors Affecting Treatment Outcomes
7
Case #1: Fit Elderly Patient With Favorable-Risk Cytogenetics
8
Treating Fit Patients With Favorable-Risk Cytogenetics
9
Case #2: Fit Elderly Patient With Poor-Risk Cytogenetics
10
Treating Fit Patients With Poor-Risk Cytogenetics
11
Treating Fit Patients With Poor-Risk Cytogenetics (cont.)
12
Considerations in Selecting a Treatment Option
13
Effect of Antecedent Hematologic Disease Other Than MDS on Outcomes Danish National Acute Leukemia Registry
14
Decitabine in AML: Multicenter DACO-016 Phase 3 Trial
15
DACO-016: OS Analysis By Time Point
16
Azacitidine in AML 20-30 and AML 30+: Austrian Azacitidine Registry
17
Azacitidine in Older Patients With AML 30+: Multicenter AZA-AML-001 Phase 3 Trial
18
AZA-AML-001: Analysis by CCR Treatment
19
AZA-AML-001: Analysis of Patients With AML-MRC by CCR Treatment
20
Hematologic Response With Hypomethylating Agents: DACO-016 and AZA-AML-001
21
Case #3: Unfit Elderly Patient With Comorbidities
22
Treating Unfit Elderly Patients
23
Selecting a Hypomethylating Agent in AML: Evidence From MDS
24
Selecting a Hypomethylating Agent in AML: DACO-016, AZA-AML-001, and Austrian Azacitidine Registry
25
Assessing Response to Hypomethylating Agents
26
Managing Toxicities Associated With Hypomethylating Agents
27
Conclusions
28
Abbreviations
29
Abbreviations (cont)
30
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.